Image source: Exelixis.
Exelixis (NASDAQ: EXEL) offered a first look at the launch of the biotech’s new kidney cancer drug Cabometyx during its second-quarter earnings report. Investors seem to like the results, with shares up 21% at 1:05 p.m. EDT, but it takes a little manipulation of the numbers to see why.